Hepatitis B: A Comprehensive Overview of Transmission, Prevention, and Clinical Management

Hepatitis B: Overview, Transmission, Prevention, and Management

Hepatitis B is a viral infection caused by the Hepatitis B virus (HBV), a highly contagious pathogen that primarily targets the liver. Despite significant advances in prevention and treatment, HBV remains a global public health concern, affecting hundreds of millions of people worldwide. Its clinical manifestations range from asymptomatic infection to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC).

1. Epidemiology

Hepatitis B is endemic in many regions, including parts of Africa, Asia, and the Pacific. Transmission occurs easily, and chronic infection is more common when exposure happens early in life. Worldwide efforts—particularly vaccination programs—have reduced new infections but have not eliminated the disease burden.

2. Modes of Transmission

HBV spreads through contact with infected blood or bodily fluids. The major transmission routes include:

2.1 Perinatal Transmission

From an infected mother to her infant during childbirth

Most common route in high-prevalence countries

Without intervention, the risk of chronic infection in newborns is extremely high

2.2 Horizontal Transmission

Exposure to infected blood in early childhood

Sharing personal items (razors, toothbrushes)

Close household contact in endemic regions

2.3 Sexual Transmission

Unprotected sexual intercourse with an infected partner

HBV is significantly more infectious than HIV

2.4 Transmission via Blood Exposure

Needle sharing

Unsafe medical or dental procedures

Occupational exposure among healthcare workers

Blood transfusion (rare where screening is available)

3. Clinical Presentation

Hepatitis B infection may be acute or chronic.

3.1 Acute Hepatitis B

Symptoms may appear 1–4 months after exposure:

Jaundice

Fatigue

Abdominal pain

Nausea and vomiting

Dark urine and pale stool

Some individuals remain asymptomatic despite active infection.

3.2 Chronic Hepatitis B

Defined by persistence of HBsAg for more than 6 months.

Potential outcomes include:

Chronic active hepatitis

Liver fibrosis

Cirrhosis

Hepatocellular carcinoma

Chronic infection is often silent until significant liver damage occurs.

4. Diagnosis

Diagnosis is based on serological markers and liver function tests.

Key Diagnostic Markers

HBsAg: Indicates active infection

Anti-HBs: Indicates immunity

HBeAg: Suggests high viral replication

Anti-HBc: Indicates prior exposure

HBV DNA: Measures viral load

Ultrasound and fibrosis assessments help determine liver damage.

5. Prevention

5.1 Vaccination

The HBV vaccine is safe, effective, and the cornerstone of prevention.

Recommended for all infants, healthcare workers, and high-risk individuals

Provides more than 95% protection

5.2 Maternal and Neonatal Prevention

Screening of pregnant women

Administering HBV vaccine + HBIG to newborns of infected mothers

Dramatically reduces perinatal transmission

5.3 Safe Practices

Avoid sharing needles and personal items

Safe sexual practices

Ensuring sterilized medical equipment

Blood screening before transfusion

6. Treatment

Treatment depends on viral load, liver function, and disease stage.

6.1 Antiviral Medications

Long-term antiviral therapy helps suppress viral replication and limit liver damage. Common agents include:

Tenofovir (TDF or TAF)

Entecavir

These medications have high potency and low resistance rates.

6.2 Monitoring

Patients require regular monitoring of:

HBV DNA levels

Liver enzymes

Liver fibrosis

Screening for hepatocellular carcinoma

6.3 Liver Transplantation

In advanced cirrhosis or liver cancer, transplantation may be necessary.

7. Public Health Impact

Hepatitis B remains a leading cause of chronic liver disease globally. Effective vaccination programs, improved screening, and accessible antiviral therapy are key strategies to reduce morbidity and mortality.